Business Context and Reporting Period
Company: LeMaitre Vascular, Inc. (LMAT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: LeMaitre is a global provider of medical devices and human tissue cryopreservation services used primarily in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company operates as a single segment, focusing on vascular surgeons and, to a lesser extent, cardiac and general surgeons. Its strategy relies on a direct sales force (95% of sales), niche product segments, and acquisitions.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Net Sales | $249.6 million | $219.9 million | +14% |
| Gross Profit | $178.5 million | $150.9 million | +18% |
| Gross Margin | 71.5% | 68.6% | +290 bps |
| Operating Income | $67.9 million | $52.3 million | +30% |
| Net Income | $57.7 million | $44.0 million | +31% |
| Diluted EPS | $2.52 | $1.93 | +31% |
| Operating Cash Flow | $81.3 million | $44.1 million | +84% |
| Cash & Equivalents | $28.2 million | $25.6 million | N/A |
| Short-term Marketable Securities | $330.9 million | $274.1 million | N/A |
| Convertible Senior Notes (Principal) | $172.5 million | $172.5 million | N/A |
Note: 2025 results include a $4.8 million benefit from the Employee Retention Credit (ERC), which favorably impacted gross margin by 109 basis points and reduced operating expenses.
Material Changes vs. Prior Period
- Revenue Growth: Driven by higher average selling prices, increased unit volumes, the European launch of the Artegraft bovine graft, and sales force expansion. EMEA sales grew 22%, outpacing Americas (10%) and Asia Pacific (10%).
- Margin Expansion: Gross margin improved to 71.5% due to the ERC benefit, manufacturing efficiencies, and price increases. This was partially offset by higher shipping costs and a shift toward lower-margin allograft services.
- Expense Management: Operating expenses increased 12% to $110.6 million. Sales and marketing expenses rose 17% due to headcount growth (160 reps) and wage increases. R&D expenses decreased 10% primarily due to lower third-party service fees related to MDR activities.
- Product Portfolio: Biologic products represented 53% of sales. The company terminated its distribution agreement with Elutia ($1.8M revenue) and wound down several product lines (PeriVu, CardioCel 3D, DuraSure, AnastoClip AC in North America).
- Acquisitions: In December 2025, the company agreed to acquire the AndraValvulotome business for $1.8 million plus up to $0.8 million in contingent payments.
Guidance, Outlook, and Risks
- Outlook: Management expects to fund operations and capital expenditures from existing cash, marketable securities, and operating cash flow. No specific numerical guidance for 2026 was provided in the text.
- Regulatory Milestones: The company has received substantially all MDR CE marks (22) and 18 of 22 UKCA marks. It anticipates commencing allograft distribution in Germany in H1 2026 and Ireland by the end of 2026.
- Cybersecurity Incident: In January 2026, the company experienced a cybersecurity incident. Critical systems were restored, and operations continued with minimal disruption. Management does not currently expect a material financial impact, though the investigation is ongoing.
- Key Risks:
- Regulatory Compliance: An FDA warning letter was issued in August 2025 regarding the North Brunswick facility; the company has addressed observations and awaits reinspection.
- Debt Servicing: The company has $172.5 million in 2.50% Convertible Senior Notes due 2030. Conversion could result in dilution or cash settlement impacting liquidity.
- Supply Chain: Reliance on sole-source suppliers for key components and human tissue procurement organizations.
- ERP Implementation: Ongoing rollout of a new enterprise resource planning system internationally presents operational risks.
Investor Verification Checklist
- ERC Sustainability: Verify the extent to which 2025 profitability relies on the one-time $4.8 million Employee Retention Credit and assess organic margin trends excluding this benefit.
- Cybersecurity Impact: Monitor updates on the January 2026 cybersecurity incident to confirm no material data breaches or long-term operational disruptions occur.
- FDA Reinspection: Confirm the outcome of the FDA reinspection at the North Brunswick facility to ensure no further enforcement actions are taken.
- Debt Conversion Risk: Assess the likelihood of the Convertible Senior Notes being converted into equity, given the current stock price relative to the conversion price (~$119.51), and the potential dilution impact.
- International Expansion: Track the successful launch of allograft services in Germany and Ireland in 2026 as a key growth driver.